Sign in
Taking people in United StatesPhase 1

Tests calaspargase pegol with chemotherapy in young adults with leukemia

Tests calaspargase pegol with chemotherapy in young adults newly diagnosed with acute lymphoblastic leukemia.

Key facts

Who runs it
H. Lee Moffitt Cancer Center and Research Institute
Where
Tampa, United StatesSee the site
Trial code
Registry title
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Status
Recruiting
Phase
Phase 1
People taking part
7 people, planned
Started
1 May 2023
Planned end
Oct 2026
Type of study
Interventional
Treatments tested
  • Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)
  • Calaspargase Pegol
  • Rituximab
Record updated
6 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 50 with newly diagnosed Philadelphia-negative B- or T-cell acute lymphoblastic leukemia who recovered from the first Hyper-CVAD chemotherapy cycle (arm 1A).

Age
18 Years to 50 Years
Sex
All sexes can join.
Disease stage
Newly diagnosed Philadelphia-negative B- or T-cell acute lymphoblastic leukemia, with >10% lymphoblasts in blood or bone marrow at diagnosis. ECOG performance status 0-1.
Earlier treatment
Must have had treatment and full recovery from arm 1A of the Hyper-CVAD regimen. No induction therapy with any other regimen.
Biomarker or test result
Philadelphia negative. Heart ejection fraction ≥ 50% before arm 1A of Hyper-CVAD. Bilirubin and creatinine < 1.5x upper limit of normal. AST and ALT < 3x upper limit of normal.

Main reasons for not taking part

  • L3 type Burkitt's lymphoma
  • Active leukemia in the central nervous system
  • Down Syndrome
  • Active infection needing systemic therapy, including HIV, Hepatitis B or Hepatitis C
  • Pregnant, breastfeeding, or planning to conceive or father children during the trial

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Pathologically confirmed Philadelphia negative B- or T-cell acute lymphoblastic leukemia, with >10% peripheral blood or bone marrow lymphoblasts at diagnosis
  • Treatment and full recovery from arm 1A of the Hyper-CVAD regimen
  • Be willing and able to provide written informed consent/assent for the trial
  • Able to adhere to the study visit schedule and other protocol requirements
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Cardiac ejection fraction ≥ 50% by echocardiography or MUGA, as measured prior to arm 1A of Hyper-CVAD
  • Serum bilirubin and creatinine < 1.5x upper limit of normal (ULN). AST and ALT must be <3x ULN
  • Females of childbearing potential (FCBP) must have a negative serum pregnancy test at screening. A FCBP is considered when a sexually mature female: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months
  • A FCBP must agree to use of two methods of highly effective non-hormonal contraception, be surgically sterile, or abstain from heterosexual activity for the course of the study through 3 monthsafter the last dose of study treatment
  • Male subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 30 days after the last dose of study therapy. Men must agree to not donate sperm during and after the study for 3 months

Who cannot take part

  • Induction therapy with any regimen other than Hyper-CVAD 1A
  • Any major surgery or radiation therapy within four weeks
  • Recurrent thrombosis, or non-central venous catheter associated thrombosis within 3 months prior to enrollment
  • Diagnosis of Down Syndrome
  • Any active infection requiring systemic therapy, including HIV, Hepatitis B, and/or Hepatitis C
  • Severe comorbid conditions for which life expectancy would be <6 months
  • Patients with active (uncontrolled, metastatic) second malignancies are excluded
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator (including but not limited to unstable angina, pre-existing liver disease, recurrent pancreatitis, uncontrolled diabetes, hypertriglyceridemia, pulmonary hypertension, or severeheart failure (New York Heart Association Class III-IV)
  • Diagnosis of L3 type Burkitt's lymphoma
  • Clinical evidence of active central nervous system (CNS) leukemia
  • Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 3 months after the last dose of trial treatment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 50 years old?

Where in United States

  • Moffitt Cancer CenterTampa, United StatesContact: Hannah LewisTaking people

About the trial

What the trial wants to find out

The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.

The group in the trial

  • Hyper-CVAD + Calaspargase pegol TreatmentTreatment being tested

    Participants will receive calaspargase pegol administered over 1 hour with each cycle of Hyper-CVAD, mini-CVD, and late intensification, beginning with Cycle 1B. Responding patients will have dose reduction of HyperCVAD for Cycles 2B-4B. Participants with CD20+ ALL will also be given Rituximab once per cycle.

    Treatment: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, and Rituximab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single-Arm, Open-Label Phase 1b Study of Hyper-CVAD + Calaspargase Pegol in Young Adults With Newly Diagnosed Acute Lymphoblastic Leukemia
Plain-language title
Tests calaspargase pegol with chemotherapy in young adults with leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05581030, who can take part
Record updated
6 March 2026